Miriam Paone

1.4k total citations · 1 hit paper
14 papers, 732 citations indexed

About

Miriam Paone is a scholar working on Oncology, Molecular Biology and Immunology. According to data from OpenAlex, Miriam Paone has authored 14 papers receiving a total of 732 indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Oncology, 7 papers in Molecular Biology and 3 papers in Immunology. Recurrent topics in Miriam Paone's work include Cancer Immunotherapy and Biomarkers (11 papers), Melanoma and MAPK Pathways (6 papers) and Colorectal Cancer Treatments and Studies (4 papers). Miriam Paone is often cited by papers focused on Cancer Immunotherapy and Biomarkers (11 papers), Melanoma and MAPK Pathways (6 papers) and Colorectal Cancer Treatments and Studies (4 papers). Miriam Paone collaborates with scholars based in Italy, United States and Malaysia. Miriam Paone's co-authors include Paolo A. Ascierto, Antonio Maria Grimaldi, Ester Simeone, Diana Giannarelli, Corrado Caracò, Giuseppe Palmieri, Lucia Festino, Vito Vanella, Ernesta Cavalcanti and Domenico Mallardo and has published in prestigious journals such as Journal of Clinical Oncology, International Journal of Molecular Sciences and Tetrahedron.

In The Last Decade

Miriam Paone

13 papers receiving 722 citations

Hit Papers

Baseline neutrophil-to-ly... 2018 2026 2020 2023 2018 100 200 300

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Miriam Paone Italy 5 598 275 159 81 70 14 732
Mitsunori Higuchi Japan 14 275 0.5× 170 0.6× 250 1.6× 85 1.0× 126 1.8× 77 654
Junxun Ma China 18 596 1.0× 135 0.5× 373 2.3× 95 1.2× 124 1.8× 45 796
Gerry Gin Wai Kwok China 7 343 0.6× 131 0.5× 109 0.7× 60 0.7× 79 1.1× 10 518
Mohamed Alshabanah Saudi Arabia 7 575 1.0× 278 1.0× 104 0.7× 50 0.6× 81 1.2× 9 698
Carla M. van Herpen Netherlands 14 325 0.5× 113 0.4× 146 0.9× 98 1.2× 195 2.8× 27 608
Giulia Mazzaschi Italy 11 444 0.7× 166 0.6× 254 1.6× 50 0.6× 130 1.9× 54 634
Charlotte Domblides France 14 404 0.7× 205 0.7× 236 1.5× 105 1.3× 201 2.9× 45 734
Xiao-Jing Du China 8 497 0.8× 103 0.4× 194 1.2× 145 1.8× 67 1.0× 9 677
Jeltje F. de Vries Netherlands 10 747 1.2× 225 0.8× 669 4.2× 80 1.0× 122 1.7× 15 1.2k
Gregory Pennock United States 8 384 0.6× 153 0.6× 132 0.8× 74 0.9× 113 1.6× 22 527

Countries citing papers authored by Miriam Paone

Since Specialization
Citations

This map shows the geographic impact of Miriam Paone's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Miriam Paone with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Miriam Paone more than expected).

Fields of papers citing papers by Miriam Paone

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Miriam Paone. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Miriam Paone. The network helps show where Miriam Paone may publish in the future.

Co-authorship network of co-authors of Miriam Paone

This figure shows the co-authorship network connecting the top 25 collaborators of Miriam Paone. A scholar is included among the top collaborators of Miriam Paone based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Miriam Paone. Miriam Paone is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

14 of 14 papers shown
1.
Ottaviano, Margaret, Domenico Mallardo, Maria Grazia Vitale, et al.. (2024). Impact of sex on immune-related adverse events in patients with melanoma.. Journal of Clinical Oncology. 42(16_suppl). e21548–e21548.
2.
Ascierto, Paolo A., Pietro Quaglino, Francesco Spagnolo, et al.. (2024). Combination or sequence of vemurafenib, cobimetinib, and atezolizumab in high-risk, resectable melanoma (NEO-TIM): Primary results.. Journal of Clinical Oncology. 42(17_suppl). LBA9513–LBA9513. 2 indexed citations
3.
Mallardo, Domenico, Margaret Ottaviano, Maria Grazia Vitale, et al.. (2024). ICOSLG Is Associated with Anti-PD-1 and Concomitant Antihistamine Treatment Response in Advanced Melanoma. International Journal of Molecular Sciences. 25(22). 12439–12439. 1 indexed citations
4.
Ascierto, Paolo A., Vanna Chiarion‐Sileni, Pietro Quaglino, et al.. (2023). Neoadjuvant plus adjuvant combined or sequenced vemurafenib, cobimetinib and atezolizumab in patients with high-risk, resectable BRAF-mutated and wild-type melanoma: NEO-TIM, a phase II randomized non-comparative study. Frontiers in Oncology. 13. 1107307–1107307. 2 indexed citations
5.
Vanella, Vito, Lucia Festino, Claudia Trojaniello, et al.. (2019). The Role of BRAF-Targeted Therapy for Advanced Melanoma in the Immunotherapy Era. Current Oncology Reports. 21(9). 76–76. 17 indexed citations
6.
Capone, Mariaelena, Diana Giannarelli, Domenico Mallardo, et al.. (2018). Baseline neutrophil-to-lymphocyte ratio (NLR) and derived NLR could predict overall survival in patients with advanced melanoma treated with nivolumab. Journal for ImmunoTherapy of Cancer. 6(1). 74–74. 351 indexed citations breakdown →
7.
Grimaldi, Antonio Maria, Paolo A. Ascierto, Ester Simeone, et al.. (2016). EP-1392: The abscopal effect:efficacy of radiotherapy in patients on progression after ipilimumab 3 mg/kg. Radiotherapy and Oncology. 119. S649–S650. 1 indexed citations
8.
Simeone, Ester, Antonio Maria Grimaldi, Lucia Festino, et al.. (2015). Correlation between BRAF mutational status and clinical response to pembrolizumab in advanced melanoma patients. Journal for ImmunoTherapy of Cancer. 3(Suppl 2). P134–P134. 1 indexed citations
9.
Grimaldi, Antonio Maria, Ester Simeone, Diana Giannarelli, et al.. (2014). Abscopal effects of radiotherapy on advanced melanoma patients who progressed after ipilimumab immunotherapy. OncoImmunology. 3(5). e28780–e28780. 290 indexed citations
10.
Grimaldi, Antonio Maria, Ester Simeone, Diana Giannarelli, et al.. (2014). Efficacy of radiotherapy in patients on progression after treatment with ipilimumab 3 mg/kg. Journal of Translational Medicine. 12(Suppl 1). O6–O6. 3 indexed citations
11.
Simeone, Ester, Antonio Maria Grimaldi, Assunta Esposito, et al.. (2014). Serious haematological toxicity during and after ipilimumab treatment: a case series. Journal of Medical Case Reports. 8(1). 240–240. 41 indexed citations
12.
Simeone, Ester, Maria Fiammetta Romano, Antonio Maria Grimaldi, et al.. (2014). High expression of a spliced variant of FKBP51 in peripheral blood mononuclear cells of melanoma patients may be related to PDL-1 on tumour and predictive of response to Ipilimumab. Journal for ImmunoTherapy of Cancer. 2(S3). 1 indexed citations
13.
Grimaldi, Antonio Maria, Ester Simeone, Diana Giannarelli, et al.. (2013). The abscopal effect: efficacy of radiotherapy in patients on progression after treatment with ipilimumab 3 mg/kg. Journal for ImmunoTherapy of Cancer. 1(S1). 3 indexed citations
14.
Carbone, Marianna, Laura Núñez‐Pons, Miriam Paone, et al.. (2012). Rossinone-related meroterpenes from the Antarctic ascidian Aplidium fuegiense. Tetrahedron. 68(18). 3541–3544. 19 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026